(R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-0825
Abstract: Oncogenic mutations in isocitrate dehydrogenase (IDH)-1 and -2 occur in a wide range of cancers, including acute myeloid leukemia (AML) and glioma. Mutant IDH enzymes convert 2-oxoglutarate (2OG) to (R)-2-hydroxyglutarate ((R)-2HG)), an oncometabolite that is… read more here.
Keywords: idh mutant; histone lysine; idh; mutant cancers ... See more keywords